ADMA Biologics, Inc.
ADMA
$20.11
$0.391.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.62% | 43.58% | 62.22% | 65.15% | 63.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.62% | 43.58% | 62.22% | 65.15% | 63.39% |
| Cost of Revenue | 14.41% | 26.74% | 28.49% | 23.76% | 19.19% |
| Gross Profit | 41.12% | 62.77% | 112.56% | 141.16% | 162.94% |
| SG&A Expenses | 39.08% | 43.14% | 38.37% | 25.22% | 4.92% |
| Depreciation & Amortization | -78.18% | -84.31% | -70.19% | -46.41% | -23.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.28% | 30.81% | 30.17% | 22.96% | 13.81% |
| Operating Income | 41.91% | 79.43% | 223.04% | 468.86% | 8,679.78% |
| Income Before Tax | 112.35% | 270.19% | 4,715.18% | 545.16% | 421.36% |
| Income Tax Expenses | -1,127.41% | -1,558.01% | -11,193.78% | -- | -- |
| Earnings from Continuing Operations | 207.41% | 500.57% | 5,772.73% | 799.98% | 398.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 207.41% | 500.57% | 5,772.73% | 799.98% | 398.48% |
| EBIT | 41.91% | 79.43% | 223.04% | 468.86% | 8,679.78% |
| EBITDA | 39.00% | 71.97% | 188.29% | 348.75% | 1,225.29% |
| EPS Basic | 202.99% | 491.41% | 5,113.71% | 768.86% | 368.92% |
| Normalized Basic EPS | 52.25% | 109.51% | 433.52% | 24,150.00% | 507.99% |
| EPS Diluted | 207.97% | 519.51% | 4,023.15% | 727.08% | 349.91% |
| Normalized Diluted EPS | 53.04% | 108.76% | 427.00% | 27,091.67% | 492.63% |
| Average Basic Shares Outstanding | 3.52% | 4.14% | 4.25% | 4.07% | 5.63% |
| Average Diluted Shares Outstanding | 3.63% | 4.87% | 6.39% | 7.18% | 7.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |